###### Strengths and limitations of this study

-   Developing and validating smartphone-based virtual patient (VP) as a quality assessment tool for research and routine use in rural primary healthcare centres.

-   Following an evidence-based approach to develop VP cases and scoring criteria.

-   Systematically validating the VP assessment tool via a cross-national multicentre study.

-   The extent to which the VP assessment will reflect practitioners' real clinical practice needs to be verified.

Introduction {#s1}
============

Universal health coverage (UHC) is a paramount goal of health system development for countries at all income levels.[@R1] The achievement of UHC is not possible without primary healthcare services,[@R1] which ensure integrated care close to the population they serve and link to the health-related sustainable development goals.[@R2] However, service coverage alone cannot improve health outcomes if the quality of care is poor. Despite efforts devoted to improving healthcare services, there is a lack of scientific evidence on the quality of primary healthcare in resource-poor settings, particularly of low-income and middle-income countries (LMICs).[@R3]

This scarcity of evidence may partially result from the limited availability of valid, low cost and easy-to-implement quality assessment tools.[@R7] As defined by Donabedian's framework, healthcare quality can be evaluated by the *structure* of care (eg, staff, equipment), the *process* of care delivery (eg, doctor-patient interactions) and health *outcomes* (eg, death or complications).[@R8] Increasingly, process measures are being used, because of their advantages in terms of frequent and timely evaluation and the usefulness in improving practice.[@R9] The 'gold standard' of assessing process is the unannounced standardised patient (USP), namely a trained actor who simulates the symptoms, signs and emotions of a real patient in a standardised fashion and presents himself or herself unannounced to clinics to assess care quality.[@R11] USP can reduce recall bias better than patient exit interviews, minimise the Hawthorne effect that inevitably occurs in direct observation and allow for comparisons between users as case-mix and patient-mix are controlled.[@R3] Nonetheless, the USP can only portray a limited number of conditions without obvious physiological symptoms and risk of invasive examinations. Also, training and implementation of USP can require substantial personnel and resources, making USP impractical for large-scale and routine quality assessment.[@R12]

As an alternative, clinical vignettes or case simulations have been widely used as a low-cost and convenient method for assessing care quality.[@R9] Vignettes have been implemented in a paper-and-pencil form,[@R9] presented by an enumerator[@R5] and streamlined by a computer.[@R14] Evidence of the validity of vignettes in assessing the quality of patient care is mixed. Some studies showed that vignettes reflect clinicians' competency (know-how) rather than their actual behaviours and can lead to overestimation of clinical performance.[@R9] By contrast, other studies found that vignette-based results, particularly those streamlined by computer, are quite close to the USP-based assessment.[@R14] The enumerator-administered vignette is similar to the announced standardised patient and thus is expensive and difficult to implement.[@R5] A computerised vignette can be interactive and can more realistically represent the complexity of a clinical encounter.[@R14] As a further improvement on computerised vignettes,[@R14] smartphone virtual patients (VPs) create high-fidelity, visualised and interactive simulations that replicate clinical complexity and can be easily implemented at a low marginal cost.[@R17] Although VPs cannot remove the Hawthorne effect, their advanced features may reduce the measurement gap between competency and actual practice.[@R10] While VPs have been used in medical education to train and test clinical skills such as clinical reasoning, diagnosis and therapeutic decisions,[@R18] their relative validity as a measure of quality of care has yet to be studied. Strengths and limitations of the abovementioned three methods are compared in [table 1](#T1){ref-type="table"}.

###### 

Strengths and limitations of quality assessment measures

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Process measure of quality         Strengths                                                              Limitations                                      Assessment level
  ---------------------------------- ---------------------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------
  Unannounced standardised patient   Standardised, controlling for case-mix and patient- mix;\              Expensive\                                       *Action* (Do)\
                                     Unannounced, no Hawthorne effect (if not be detected);\                Limited medical conditions\                      *Gold standard*
                                     Reduced recall bias                                                    First-visit bias\                                
                                                                                                            Selection bias if informed consent is required   

  Clinical vignettes                 Cost-effective;\                                                       Hawthorne effect\                                *Competence* (Know how)\
                                     Suitable for large scale and cross-system comparison;\                 Selection bias                                   *Overestimating* care quality (best answers) or similar
                                     Covering all illnesses;\                                                                                                
                                     Accounting for case-mix and patient-mix.                                                                                

  Virtual patients                   Interactive\                                                           Hawthorne effect\                                *Performance* (Show how)\
                                     Real-time response and automatic record\                               Selection bias\                                  *?*
                                     Highly standardised\                                                   High cost in initial development                 
                                     Scalability and low marginal cost\                                                                                      
                                     Efficient delivery: anytime, anywhere Suitable for large scale study                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the present study, we propose to adapt smartphone-based VP for medical education as a quality-of-care assessment tool, given its advantages in (1) standardisation (VPs are highly standardised, ensuring consistent assessments across users), (2) *flexibility* (assessments can be delivered by smartphones for multiple users at any time, anywhere, providing data connectivity is available), (3) *scalability* (VPs can be modified to demonstrate and assess almost any clinical conditions with low marginal cost) and (4) *training* (VPs can also be used as a training tool to improve healthcare quality and thus to address the 'so what' question after quality assessment). These characteristics may especially benefit quality assessment and improvement in rural primary care settings, where communities are geographically scattered and difficult to reach and manage.

Therefore, our study aims to develop and validate *smartphone-based VPs* against USPs as a quality assessment tool that can be used both for research purposes and for routine evaluation of quality of primary healthcare provided by primary health centres (PHCs) in rural areas. To maximise its validity,[@R14] we will systematically construct high-fidelity VP cases to reflect clinical complexity in rural PHC contexts with real-time patient-doctor interactions and temporal constraints and use evidence-based quality scoring criteria; additionally, we will make the VP-based test anonymous to minimise the Hawthorne effect. The initial phase of the study will mainly focus on rural China, while the ultimate goal is to develop and validate tools that can have a broad application in other LMICs.

Methods and analysis {#s2}
====================

Study setting {#s2a}
-------------

The validation study will be implemented in the outpatient setting of rural PHCs (ie, township health centres and village clinics) in seven Chinese provinces (Guizhou, Sichuan, Gansu, Inner Mongolia, Shaanxi, Hunan and Guangdong). We are selecting these provinces to reflect the five strata of low-to-high life-expectancies and various burden-of-disease patterns in China[@R19] and to contrast geographic regions with diverse ethnic composition, including southwest mountainous regions, the northern plateau, the middle inland region and southeast coastal areas ([figure 1](#F1){ref-type="fig"}). Our study targets township health centres and village clinics because they provide the majority of primary healthcare in rural China.[@R20] At township health centres, primary healthcare is delivered by a workforce including licensed/unlicensed physicians, licensed/unlicensed assistant physicians and registered nurses, while at village clinics, services are mainly delivered by one full-time or part-time 'village doctor' who is a clinician with rudimentary medical training.[@R20] The outpatient setting is chosen due to the small number of inpatient cases in township health centres and village clinics. Study recruitment is expected to start from June 2018.

![Seven sample provinces in China referencing countries of equivalent life expectancy in parentheses.](bmjopen-2017-020943f01){#F1}

VP case development {#s2b}
-------------------

### VP case selection {#s2b1}

We intend to select 10 cases that together can represent the work of rural PHCs. The selection of the VP cases will be based on the following criteria: (1) high frequency of clinical encounters in the primary care settings in rural areas and/or (2) association with significant disease burden; (3) representation of the major areas of work of PHCs in rural China overall (eg, public health service delivery, chronic disease management, infectious disease control, health education and patient-centred care) and (4) suitability for the USP methodology (eg, no obvious physiological signs, low risk for invasive tests) for the sake of criterion validation in the current study. A case selection committee will comprise a range of stakeholders, including physicians, public health practitioners, policy-makers and members of the research team. Based on the literature review, the research team will prepare a shortlist of the 30 most frequently seen conditions in township health centres and village clinics reported by either community dwellers[@R24] or rural PHC clinicians (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}) from which the committee will select.

10.1136/bmjopen-2017-020943.supp1

### VP case design {#s2b2}

The 10 selected VP cases will then be constructed individually by 10 case-specific development teams ([figure 2](#F2){ref-type="fig"}). These teams consist of one *condition expert* from the relevant specialty of a tertiary teaching hospital who will be responsible for drafting the VP case; an *evidence-synthesis group* involving epidemiologists and evidence-based researchers who will search and synthesise evidence about the selected condition for the condition expert to work on; a *clinical consensus group* which consists of several condition-related clinical experts who will review the corresponding case from a scientific perspective; an overall all-condition shared *context-expert panel*, which includes clinicians and health managers from community health centres, township health centres and village clinics, who will review the contextual appropriateness of the cases for the rural PHC setting and a *case coordinator* who will coordinate development of each case.

![Virtual patient case development team role and responsibilities.](bmjopen-2017-020943f02){#F2}

Each VP case will be structured into five domains---medical history, physical examination, laboratory and imaging studies, diagnosis and management and treatment plan---to simulate real-life clinical scenarios.[@R11] The structured VP cases will permit the examinee's performance in each domain to be evaluated and for performance scores to be aggregated across conditions. In addition to these five condition-related domains, another practice contextual adjustment will be built into each case to consider medical resource constraints in rural practices (eg, availability of basic medical equipment and medicines).

### Scoring criteria {#s2b3}

Care quality scoring criteria will be developed for each VP case. These criteria include *process quality*, the *accuracy of diagnosis and* the *appropriateness of the treatment and management plan*.[@R3] Process quality will be evaluated in reference to a clinical process checklist (to be detailed later) including all necessary questions that should be asked and physical examinations that should be performed by clinicians, together with redundant or even potentially harmful practices. Diagnoses will be rated as correct, partially correct or incorrect based on predetermined standards. The treatment and management plan will be considered appropriate if the clinician prescribes any of the correct medications or refers the patient to a higher-level physician depending on the VP case.

In addition, *cost of care* and *time-spent per encounter* will also be recorded. Patient costs will cover medication fees and clinic fees charged per case. In order to link clinician reaction time to each domain and to impose the temporal constraints seen in real clinical practices, the entire clinician-VP interaction process will be timed. This will include time spent on taking history, conducting physical examinations, prescribing drugs and treatments and any interruptions.

A systematic evidence-based approach will be adopted to developing the scoring checklist for the treatment and management plan (online [supplementary appendix 2](#SP1){ref-type="supplementary-material"}). Briefly, the evidence-synthesis group will systematically search and extract condition-specific checklist items and standards from clinical guidelines, reputable textbooks and systematic reviews, among others, in that order. The quality of the evidence will then be rated by the Appraisal of Guidelines for Research & Evaluation II (AGREE II)[@R25] or the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) according to its type.[@R26] Afterwards, the clinical consensus group and the contextual-expert panel will review and revise initial standards using a Delphi process.[@R27]

VP case external review {#s2c}
-----------------------

To validate the content of VP cases, an independent expert panel of physicians, general practitioners and rural PHC clinicians who otherwise are not involved in the study, will be convened to review the cases for content accuracy and appropriateness. The content validation involves qualitative and quantitative phases. In the qualitative phase, the expert panel will be required to evaluate the cases with respect to the following: overarching assessment goal, representativeness of the goal and test items to each domain, the logical relationship of the content tested and the appropriate wording, grammar, understandability and relevance to the rural PHC context. The panel will also record their suggestions, if any, next to each item. Modified VP cases will then be given back to the expert panel for quantitative evaluation. They will be asked to assess the cases for simplicity and clarity as well as necessity and relevance to the assessment, using a four-point Likert scale ranging from 1 (the lowest) to 4 (the highest). The content validity index will be computed for each domain and for the entirety of VP cases.[@R28]

Technical implementation {#s2d}
------------------------

Revised VP cases will be implemented on *CureFUN*, an existing smartphone-based training platform using VPs with special customisations and set-up to suit the assessment purpose. A live demonstration of a simplified VP can be accessed from <http://www.curefun.com/zhiqu_front/www/experience/experience.html>\#/caseList and is also illustrated in online [supplementary appendix 3](#SP1){ref-type="supplementary-material"}. The smartphone-based VP assessment tool will present interactive clinical scenarios and will automatically record each examinee's diagnosis pathway and grade it against the scoring criteria ([figure 3](#F3){ref-type="fig"}).

![Main components of smartphone-based virtual patient programme.](bmjopen-2017-020943f03){#F3}

Feasibility study {#s2e}
-----------------

Before a full-scale validation study, a feasibility study with 30% of the validation study sample (see study sample section) will be conducted to test the VP assessment tool's usability, accessibility and stability, particularly in remote village clinics with weak phone connectivity. Selected clinicians will be instructed to individually attempt two random VP cases within a given time, using their own smartphone devices from their workplace. Clinicians without a smartphone will be given a temporary device on which the customised *CureFUN* applications will be preinstalled. Clinicians' willingness to participate and adherence to the VP-based tests (eg, percentage completing VP cases, score of the assessment and number of attempts made at each case per person) will be automatically recorded. On completion of the cases, participants will be asked to fill in a five-point Likert-scale questionnaire regarding their subjective attitude towards the simulator VP experience (with 1 being the most negative response and 5 being the most positive), regarding ease of use, their experience of the assessment process and outcome, realism, device competence, accessibility and other general comments. These results will be used to determine the face validity of the VP cases, with scores calculated by multiplying frequency (%) by positive evaluations (3--5); and scores no less than 1.5 are considered acceptable.[@R29]

Validation of VP as a quality assessment tool {#s2f}
---------------------------------------------

### Study design {#s2f1}

The prospective validation study is a nationwide multicentre study with two main purposes: (1) to assess the criterion validity of the VP-tool in assessing the quality of primary healthcare, by analysing its measurement concordance against the standard USP measure and (2) to test the reliability of the VP tool, by examining its internal consistency and the stability of repeated VP assessments on the same subjects.

### Study sample {#s2f2}

From each of our seven sample provinces, two counties will be selected with sufficient variations in socioeconomic conditions, demographics and disease burdens between them while also approximating the provincial condition in general. Within each county, the government registry of all township health centres and village clinics will serve as our sampling frame, which will include (1) licensed practicing physicians, (2) clinicians who have not been licensed but are providing clinical services under the supervision of licensed physicians at township health centres as well as (3) full-time or part-time village clinicians. Clinicians visiting on a temporary basis (often senior clinicians sent by higher level medical institutions to support the development of township health centres), nurses and allied health workers without prescription privileges will be excluded.

The sample size calculation is based on individual VP/USP-clinician encounter and ensures sufficient power to detect variations at individual case level per county. For village clinics, one VP/USP case will be examined at a time to minimise the detection of USPs. Assuming a 5% type I error and 80% power, to determine whether a moderate concordance correlation coefficient[@R30] of 0.90[@R31] between VP and USP differs from zero, seven paired VP/USP-clinician encounters will be required for each of the 10 cases per county. As a stratified sampling strategy will be deployed that first samples townships and then villages from each township, sample size calculations need to take into account the design effect. Assuming an intraclass correlation of 0.05 and six village clinics per township, then nine paired VP/USP-clinician encounters is needed. These nine paired VP/USP-clinician encounters will be assigned to three township health centres and six village clinics using probability proportional to size. These nine paired VP/USP-clinician encounters will be assigned to township health centres and village clinics based on the ratio of the total number of clinicians at township health centres to the total number of village clinicians for each county. There are 1260 VP/USP-clinician encounters across our 7 study provinces for all 10 VP cases. [Figure 4](#F4){ref-type="fig"} shows the sampling process and study flow for one VP case using Guizhou Province (Danzhai County) as an example.

![Sampling and study process for one VP case in Danzhai County, Guizhou Province.](bmjopen-2017-020943f04){#F4}

### Criterion validity {#s2f3}

Criterion validity[@R32] of the VP to assess quality of care will be evaluated primarily by its measurement concordance against the USP measure as the recognised gold standard[@R33] for assessing quality of care in practice. The USPs will be developed in a related study, sharing the development teams for VP and a similar development process. The method of fielding USPs in rural China will follow a similar approach to those of the previous USP study in rural China.[@R3] Identical quality scoring criteria, described above, will be applied to scores. Each selected clinician will first see a USP (to avoid the practice effect due to the USP's unannounced feature) and then complete a smartphone-based VP assessment of the same condition. The clinician to be assessed will be randomly selected onsite by the USP from any on-duty clinicians on the day of the USP visit to the sampled township health centre and village clinics. This situation would especially apply to township health centres, as most village clinics have only one clinician (note: Chinese patients normally see their primary care clinicians as a walk-in patient and appointments are seldom needed). To record USP-clinician interactions, USPs will complete checklists immediately after their visit and retain their prescription and the fee charge slips provided by the clinician. A week after the USP clinic visit, clinicians will be assigned a smartphone-based VP assessment, which will consist of an initial demonstration VP case to allow the clinician to familiarise themselves with how the system operates and then the test VP case of the same USP condition. The VP-clinician interactions, drugs dispensed and fees charged will all be recorded automatically by the online assessment system.

The concordance of the two USP and VP assessments will then be analysed by Lin's concordance correlation coefficient (r~c~)[@R30] for continuous *process quality* scores, *fees charged* (yuan) and *time spent* (min) and the Kappa statistic[@R34] for dichotomous *diagnoses* and *treatment & management* measures. r~c~ evaluates how close pairs of observation fell on a 45° line (the perfect concordance line) through the origin in addition to their correlation. Kappa measures agreement in assessment beyond what is expected by chance alone. In addition, for continuous measures, a Bland-Altman plot will also be used to visualise the concordance.[@R35] For dichotomous measures, we will analyse their sensitivity (ie, strength to detect correct diagnosis, treatment plan, among others) and specificity (ie, strength to detect incorrect diagnosis, treatment plan, among others) using USP as the reference.

### Reliability {#s2f4}

To establish *test-retest reliability*, clinicians previously being assessed by VPs will be instructed to retake the same VP tests 4 weeks after their last assessment. The second VP test is set 1 month later than the first to reduce the practice effect,[@R37] assuming the clinician's general medical knowledge remains constant.[@R32] The concordance of the two repeated tests indicates the stability of the VP assessment tool.[@R32] Similar concordance measures (ie, r~c~ for continuous and Kappa for dichotomous measures) as described above will be used. *Internal consistency*, the intercorrelation of scores for process quality indicators, will be computed by Cronbach's alpha coefficients (α),[@R38] with α\>0.7 representing acceptable reliability.[@R39] [Table 2](#T2){ref-type="table"} summarises the validity, reliability and feasibility measures that will be examined in our study.

###### 

Main validation domains of the study

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Domain                    Indicator                                          Data collection                                                                                                                         Statistical analysis                                                                                                                                                                                                                                    
  ------------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Content validity          Content validity index                             VP case review                                                                                                                          Evaluations by an expert panel after reviewing VP cases, measured by a 4-point Likert scale (1=lowest, 4=highest).                                                                                                                                      CVI for VP case and for specific VP domain will be computed, where CVI=number of raters giving a rating of 3 or four divided by the total number of raters.

  Feasibility               Willingness to participate;\                       Feasibility study                                                                                                                       The subsample of clinicians' interactions with the two VP cases will be recorded by the online assessment                                                                                                                                               Willingness to Participate=clinicians taking the VP tests divided by the percentage of clinician selected Adherence rate=clinicians completed two VP cases divided by the percentage of clinicians taking VP tests
                            Adherence rate                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Face validity             Satisfying score                                   Clinicians' subjective attitude towards the VP test experience measured by a 5-point Likert scale (1=most negative, 5=most positive).   Satisfying score for VP case and for specific aspects (eg, usability, accessibility, etc) will be computed, where satisfying score=frequency multiply by positive evaluations (3--5) and scores≥1.5 are considered acceptable.                          

  Criterion validity        Concordance correlation coefficient (r~c~);\       Validation study                                                                                                                        The same clinician receives a USP visit and a VP test for a matching condition. The USP-clinician interaction is evaluated by the USP using the checklist, including fees and time per visit; while VP-clinician interaction is graded by the system.   The concordance of VP-test scores against USP-test score (gold standard) or two-repeated VP-tests will be examined by r~c~ for continuous process quality scores, fees charged (yuan) and time spent (min) and Kappa for dichotomous diagnoses and treatment and management measures.
                            Kappa statistic                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Test-retest reliability   Repeat VP-tests on the same clinician in a month                                                                                                                                                                                                                                                                                                                                                                                                   

  Internal consistency      Cronbach's alpha coefficient (α)                   VP-test scores on a single occasion                                                                                                     Intercorrelation of scores for process quality indicators with α\>0.7 is acceptable.                                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CVI, content validity index; VP, virtual patient.

Patient and public involvement {#s2g}
------------------------------

We will seek feedback from clinicians and patient representatives in the feasibility study and use their feedback to refine the VP cases. Our USPs will be lay people trained to portray patients and assess care quality based on their interactions with clinicians. Our scoring criteria thus are also patient-centred. Furthermore, all participants will be acknowledged for their involvement in the study and will be provided with a final summary report of the study outcomes and will have free access to the VP training website. All published results will be publicly available.

Ethics and dissemination {#s3}
========================

Informed consent will be obtained from all clinicians participating in the VP tests. However, to reduce participation bias due to self-selection,[@R40] our IRB has approved the implementation of USP without prior informed consent from the individual participants, on the condition that involved clinicians will be fully deidentified and all analyses will only be conducted at the population level.[@R40] Study data will be securely stored and only deidentified information will be used for analysis. We will seek to publish study findings in peer-reviewed journals and produce reports to inform health authorities. The tools and technology developed in this study will be freely available to other LMICs for research purposes.

Discussion {#s4}
==========

To the best of our knowledge, this is the first study validating VP as a quality assessment tool in rural primary healthcare centres. This study follows an evidence-based approach to develop VP cases and scoring criteria, implements them on a widely accessible platform (ie, a smartphone) and systematically validates the VP assessment tool via a cross-national multicentre study representing rural PHCs over a wide range of geographic areas with distinct life expectancies and economic development levels. The VP assessment tool's accessibility, flexibility and scalability give it good potential to be easily adapted to other LMICs.

VP has mainly been used in medical education to train and test critical thinking,[@R18] and until recently few studies have applied the method in a practice setting to influence health provider behaviour and improve care quality.[@R43] As an extension, we propose to validate VP as a quality assessment tool delivered via widely accessible smartphones. Nevertheless, it is to be noted that given its simulated nature, the VP-test theoretically may never completely bridge the 'know-do' gap. The validation study is thus essential to quantify the concordance/discordance between VP-based and USP-based quality assessments. Our study will generate firsthand empirical evidence contributing to the understanding of the 'know-do gap'[@R5] and shed light on circumstances that cannot be tested by USPs.

A limitation of the study, however, is that, in order to test the validity of VP against USP as the reference standard, we restrict the selection of VP cases to those that can be simulated by USP. This conservative first step will nevertheless allow us to examine the extent to which VP can reflect care quality, and a follow-up study will then explore the full potential of the VP in assessing quality of care. Further, the two purposely selected counties for each province may not represent the provincial conditions entirely, although we will make every effort to consider provincial representation when selecting counties. Third, while the validation study is exclusively conducted on PHCs in rural China, the extent to which the VP assessment tool can be transported to other LMICs remains to be evaluated. Nonetheless, by implementing the study in a diverse set of Chinese provinces may improve the generalisability of our study considering the comparable life expectancies of LMICs and these provinces.
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